Overview

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Status:
Active, not recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
Phase:
Phase 3
Details
Lead Sponsor:
Liquidia Technologies, Inc.
Collaborator:
Nuventra, Inc.
Treatments:
Treprostinil